QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

OGN

QT73Organon & Co.
NYSE·Healthcare·Drug Manufacturers - General·USA
Latest market price
13.43
+0.01+0.07%
OverviewShort InterestFilings
OGNQT73Organon & Co.·NYSE
OverviewShort InterestFilings
13.43+0.07%
TA
Loading chart...
Screen all →
LLY-1.21%$1098.57JNJ-2.48%$228.39ABBV-2.08%$216.63NVS-2.52%$147.08MRK-1.36%$113.87AZN-1.66%$174.93NVO-0.76%$43.19AMGN-1.19%$337.60
Snapshot
Index-P/E14.20EPS (ttm)0.93
Insider Own1.50%
Shs Outstand262.60M
Perf Week-0.15%
Market Cap3.52BForward P/E3.69EPS next Y3.63Insider Trans0.21%Shs Float-Perf Month0.07%
Enterprise Value10.98BPEG-EPS next Q0.87Inst Own-Short Float-Perf Quarter114.19%
Income248.10MP/S0.57EPS this Y265.28%Inst Trans-Short Ratio-Perf Half Y92.68%
Sales6.16BP/B3.87EPS next Y6.99%ROA1.89%Short Interest-Perf YTD87.31%
Book/sh3.44P/C4.11EPS next 5Y3.51%ROE29.87%52W High13.49 -0.44%Perf Year36.35%
Cash/sh4.25P/FCF5.74EPS past 3/5Y-ROIC5.16%52W Low5.69 136.03%Perf 3Y-
Dividend Est.0.08 (0.60%)EV/EBITDA7.94Sales past 3/5Y0.23% -0.99%Gross Margin53.11%Volatility0.27% 0.29%Perf 5Y-
Dividend TTM0.08 (0.60%)EV/Sales1.78EPS Y/Y TTM0.60%Oper. Margin19.23%ATR (14)0.10Perf 10Y-
Dividend Ex-DateMay 11, 2026Quick Ratio1.42Sales Y/Y TTM-3.75%Profit Margin3.99%RSI (14)72.22Recom3.33
Dividend Gr. 3/5Y-32.79% -Current Ratio1.97EPS Q/Q-30.39%SMA200.22%Beta0.86Target Price11.33
Payout8.94%Debt/Eq9.49Sales Q/Q-3.50%SMA508.93%Rel Volume0.51Prev Close13.42
Employees10,000LT Debt/Eq11.64EarningsAug 04SMA20047.64%Avg Volume9.84MPrice13.43
IPO DateMay 14, 2021Option/ShortYes / YesEPS/Sales Surpr.-14.46% -1.88%Net Debt/EBITDA5.39Volume5,056,160Change0.07%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-29-26DowngradeBNP ParibasOutperform → Neutral
Apr-28-26UpgradePiper SandlerUnderweight → Neutral$14
Apr-10-26ReiteratedBNP Paribas$12
Feb-24-26ReiteratedBarclaysUnderweight$7.50 → $8.00
Dec-08-25InitiatedBarclaysUnderweight$7.50
Oct-27-25ReiteratedPiper SandlerOverweight$18 → $5.00
May-15-25ReiteratedPiper SandlerOverweight$24 → $18
May-05-25ReiteratedMorgan StanleyEqual Weight$10
Sep-06-24DowngradeJP MorganNeutral → Underweight
Apr-29-24ReiteratedPiper SandlerOverweight$34 → $24
Latest News
Jun-18-26
Jun-18-2606:08AM
Organon And Samsung Bioepis Expand Their Development And Commercialization Agreement To Provide OGN With Commercialization Rights In Canada To PYZCHIVA, Samsung Bioepis's Biosimilar Referencing STELARABenzinga
Jun-17-26
Jun-17-2607:01PM
Organon & Co. (OGN) Shareholder/Analyst Call - SlideshowSeekingAlpha
Jun-10-26
Jun-10-2607:33AM
Organon's Supplemental Biologics License Application Gets FDA Approval For TOFIDENCE To Treat Chimeric Antigen Receptor T Cell-Induced Severe Or Life-Threatening Cytokine Release SyndromeBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue6,1636,2166,403
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A2,8902,8542,688
Gross Profit3,2733,3623,715
Selling, General and Administrative Excl. Other1,7251,7111,760
Research and Development363366469
Other Operating Expense0100
Operating Income1,1851,2851,486
Interest Expense492504520
Unusual Expense
———
Non-Operating Income (Expense)157356159
Net Income Before Taxes537425807
Income Taxes291238-57
Consolidated Net Income246187864
Net Income From Continuing Operations246187864
Net Income246187864
EPS (Recurring)0.950.723.36
EPS (Basic, Before Extraordinaries)0.950.723.36
EPS (Diluted)0.930.723.33
EBITDA1,3831,2821,604
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio14.449.96—
Price To Sales Ratio0.570.30—
Gross Margin53.1154.0958.02
Operating Margin19.2320.6723.21
Net Margin3.993.0113.49
Shares Outstanding260259257
Market Capitalization3,4921,857—
Operating Lease Expense
———
Insider Trading Volume
$16.31$15.16$14.02$12.87$11.72● Close Price0.00K125.44K250.88K376.32K501.75KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Holzbaur LynetteSVP and Corporate ControllerMay 06 '26Buy13.3526,448353,08052,851May 07 12:00 AM
Holzbaur LynetteSVP and Corporate ControllerMay 06 '26Sale13.3526,448353,0800May 07 12:00 AM
Karp DanielExecutive VP, Corp. Dev.Mar 31 '26Option Exercise0.0036,106071,653Apr 02 12:00 AM
Stahler Rachel AChief Information OfficerMar 31 '26Option Exercise0.0037,7340120,322Apr 02 12:00 AM
WALSH MATTHEW MChief Financial OfficerMar 31 '26Option Exercise0.0067,1860220,126Apr 02 12:00 AM
Falcione AaronChief Human Resources OfficerMar 31 '26Option Exercise0.0035,8500105,265Apr 02 12:00 AM
Weaver KirkeGen. Counsel & Corp. Secy.Mar 31 '26Option Exercise0.0037,026096,147Apr 02 12:00 AM
Nisita VittorioHead of Global Business SvcsMar 31 '26Option Exercise0.0026,000073,494Apr 02 12:00 AM
Holzbaur LynetteSVP and Corporate ControllerMar 31 '26Option Exercise0.0017,682028,316Apr 02 12:00 AM
Morrissey Joseph T. Jr.Interim CEOMar 31 '26Option Exercise0.0049,1680127,907Apr 02 12:00 AM
Drinane Juliana PapaInterim Head of Mfg & SupplyMar 31 '26Option Exercise0.0032,902036,687Apr 02 12:00 AM
Arjona Ferreira Juan CamiloHead of R&D & CMOMar 31 '26Option Exercise0.0026,862034,867Apr 02 12:00 AM
Morrissey Joseph T. Jr.Interim CEOMar 29 '26Option Exercise0.0019,5040108,323Mar 31 12:00 AM
Stahler Rachel AChief Information OfficerMar 29 '26Option Exercise0.0016,4000106,510Mar 31 12:00 AM
Holzbaur LynetteSVP and Corporate ControllerMar 29 '26Option Exercise0.0010,638019,995Mar 31 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR